Schedule template 1													
	Date of publication: 30/06/2016												
	Full Name	HCOs: city where registered (Art. 3)	f Country of Principal	Principal Practice Address (Art. 3)	Unique country local identifyer <i>OPTIONAL</i> (<i>Art. 3</i>)	Donations and Grants to HCOs (Art. 3.01.1.a)				Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			
	(Art. 1.01)		Practice (Schedule 1)				Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract	TOTAL OPTIONAL	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	Popovic Vera	Belgrade	Serbia	Neuroendocrine Unit, Endocrinology Clinic, University Clinical Center	-	N/A	N/A	-	1248,00	-	-	1248,00	
s	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
HC H	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2					N/A	N/A	-	1161,00	-	-		
Ŧ	Number of Recipients in aggregate disclosure- Art. 3.2					N/A	N/A	-	1	-	-		
	% of the number Recipients included in the aggregate disciosure in the total number of Recipients disciosed Art. 3.2					N/A	N/A	-	50%	-	-		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	-					-	-	-	-	-	-		
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2					-	-	-	-	-	-		
S	Number of Recipients in aggregate disclosure- Art. 3.2					-	-	-	-	-	-		
Ŷ	% of the number Recipients included in the aggregate disciosure in the total number of Recipients disciosed- Art. 3.2					-	-	-	-	-	-		
	AGGREGATE DISCLOSURE												
R&D	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1												